Half-Brain Delineation for Prediction of Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy

Qing-Hua Du1, Yi-Xiu Gan1, Ren-Sheng Wang2, Wen-Qi Liu1, Jian Li1, Fei-Fei Liang2, Xiang-De Li1, Hui-Jun Zhu1, Xue Ou1, Qiu-Lu Zhong1, Dan-Jing Luo1, Zhi-Peng Zhu1 and Shang-Yong Zhu3*

1 Department of Radiation Oncology, Second Affiliated Hospital of Guangxi Medical University, Nanning, China; 2 Department of Radiation Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China; 3 Department of Medical Ultrasound, First Affiliated Hospital of Guangxi Medical University, Nanning, China

Purpose: To investigate the role of half-brain delineation in the prediction of radiation-induced temporal lobe injury (TLI) in nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT).

Methods and Materials: A total of 220 NPC cases treated with IMRT and concurrent platinum-based chemotherapy were retrospectively analyzed. Dosimetric parameters of temporal lobes, half-brains, and brains included maximum dose (Dmax), doses covering certain volume (DV) from 0.03 to 20 cc and absolute volumes receiving specific dose (VD) from 40 to 80 Gy. Inter-structure variability was assessed by coefficients of variation (CV) and paired samples t-tests. Receiver operating characteristic curve (ROC) and Youden index were used for screening dosimetric parameters to predict TLI. Dose/volume response curve was calculated using the logistic dose/volume response model.

Results: CVs of brains, left/right half-brains, and left/right temporal lobes were 9.72%, 9.96%, 9.77%, 27.85%, and 28.34%, respectively. Each DV in temporal lobe was significantly smaller than that in half-brain (P < 0.001), and the reduction ranged from 3.10% to 45.98%. The area under the curve (AUC) of DV and VD showed an "increase-maximum-decline" behavior with a peak as the volume or dose increased. The maximal AUCs of DVs in brain, half-brain and temporal lobe were 0.808 (D2cc), 0.828 (D1.2cc) and 0.806 (D0.6cc), respectively, and the maximal AUCs of VDs were 0.818 (D75Gy), 0.834 (V72Gy) and 0.814 (V70Gy), respectively. The cutoffs of V70Gy (0.86 cc), V71Gy (0.72 cc), V72Gy (0.60 cc), and V73Gy (0.45 cc) in half-brain had better Youden index. TD5/5 and TD50/5 of D1.2cc were 58.7 and 80.0 Gy, respectively. The probability of TLI was higher than >13% when V72Gy>0 cc, and equal to 50% when V72Gy = 7.66 cc.

Conclusion: Half-brain delineation is a convenient and stable method which could reduce contouring variation and could be used in NPC patients. D1.2cc and V72Gy of half-brain are...
INTRODUCTION

Radiation-induced temporal lobe injury (TLI) is a serious complication for nasopharyngeal carcinoma (NPC), which has profound effects on quality of life (1). Understanding the probability of developing temporal lobe injury is an important requirement of radiotherapy for NPC patients. The quantitative analysis of normal tissue effects in the clinic (QUANTEC) review showed that for conventional fractionation with doses ≤2 Gy, a 5% risk of symptomatic radiation brain necrosis is predicted at an equivalent dose of 72 Gy (2). In 2019, an international guideline on dose prioritization and acceptance criteria for NPC was developed (3). The final temporal lobe recommendation of the panel was to aim for a D0.05cc planning risk volume (PRV) dose ≤65 Gy for T1–2 tumors and ≤70 Gy for T3–4 tumors. However, the optimal dose/volume predictors for TLI still vary in different studies. A study by Sun et al. (4) reported that a D0.5cc of 69 Gy might be the dose tolerance of the temporal lobe. Other studies suggested different dose equivalents of 58 Gy (D1cc) (5), 60.3 Gy (D2cc) (6), 62.8 Gy (D1cc) (7), and 69 Gy (Dmax at 2 Gy per fraction) (8) for a 5% probability of developing temporal lobe injury at 5 years. Considering the long incubation period and few cases of radiation temporal lobe injury, more practical data are needed to support the accurate dose limit.

Accurate delineation of temporal lobe is another important requirement. Significant inter-observer variation in delineation of target volumes or normal organs has been demonstrated (9–11), which might also occur in delineation of temporal lobe (12, 13). In order to collect accurate data for TLI prediction, temporal lobes were re-contoured in some studies (6, 8, 14). Sun et al. (15) provided a contouring recommendation for temporal lobe, which reduced the delineation divergence. Temporal lobe contouring can be standardized through effective implementation of a temporal lobe contouring protocol and atlas, but it requires continuous and extensive training for beginners (13). On the other hand, magnetic resonance imaging (MRI) fusion, which makes the temporal lobe clearer, is not performed for every case.

Brain is a structure clearly defined by international guidelines (16). Surrounded by a clear skull bone, the brain could be easily delineated with little disagreement, and the automatic segmentation of brain is more feasible. However, brain is rarely contoured in NPC patients. Half-brain (left and right half-brain, corresponding to left and right temporal lobe) might be a simple substitute for temporal lobe considering that: 1) only a small high-dose volume of temporal lobe is used for TLI prediction; 2) the high-dose volume is always concentrated in temporal pole. Therefore, the small high-dose volume is present simultaneously in half-brain. Even the whole brain might predict TLI independently. In order to confirm the role of half-brain delineation in TLI prediction, this study compared the dosimetric parameters of temporal lobe and half-brain, and assessed the predictive ability of brain, half-brain and temporal lobe for TLI.

MATERIALS AND METHODS

Patient Selection

From January 2009 to May 2015, 220 NPC patients treated with IMRT and concurrent platinum-based chemotherapy at the First Affiliated Hospital of Guangxi Medical University were retrospectively reviewed (Table 1). Patients were followed every 3 months in the first 2 years and every 6 months during the next 3 years, and then annually thereafter. The median follow-up time of was 69.3 months (range, 61.1–120.8 months). The incidence of TLI was 34.5%, and the median latency was 39.3 months (range, 1.4–78.7 months).

| Items | No. | Injury | Non-injury | P |
|-------|-----|--------|------------|---|
| Gender |     |        |            |   |
| Male   | 166 | 58 (76.3%) | 108 (75.0%) | 0.829 |
| Female | 54  | 18 (23.7%) | 36 (25.0%)  |   |
| Age |     |        |            |   |
| >60    | 50  | 19 (25.0%) | 31 (21.5%)  | 0.559 |
| ≤60    | 170 | 57 (75.0%) | 113 (78.5%) |   |
| Diabetes | |        |            |   |
| Yes    | 9   | 3 (3.9%)  | 6 (4.2%)    | 0.938 |
| No     | 215 | 73 (96.1%) | 138 (95.8%) |   |
| Hypertension | |        |            |   |
| Yes    | 11  | 4 (5.3%)  | 7 (4.9%)    | 0.896 |
| No     | 215 | 72 (94.7%) | 137 (95.1%) |   |
| T stage* | |        |            | <0.001 |
| T1     | 0   | 0 (0%)   | 0 (0%)      |   |
| T2     | 25  | 2 (2.6%)  | 23 (16.0%)  |   |
| T3     | 86  | 15 (19.7%) | 71 (49.3%)  |   |
| T4     | 109 | 59 (77.6%) | 50 (34.7%)  |   |

*When T stage and the following dosimetric parameters were analyzed together in multivariate analysis, T stage was removed (P > 0.05).
Radiation Therapy and Structure Delineation

A neck and shoulder thermoplastic mask was used to fix the patients. Radiation planning was designed and optimized using inverse treatment planning system (software version: Pinnacle 9.8 and Varian Eclipse 9.8), at least 5 isocentric fields being set up. The prescribed dose was 68 to 72 Gy to the planning target volume (PTV) of gross tumor volume (GTV), 60 to 64 Gy to the PTV of high-risk clinical target volume (CTV), and 50 to 54 Gy to the PTV of low-risk CTV. The doses for each critical organ were limited, as described in the Radiation Therapy Oncology Group 02-25 protocol (eg, point, 65 Gy and 1% volume, 60 Gy for temporal lobes) (7). When doses exceeded limits inevitably, they were accepted by consensus and adequate communication with patients. All patients received full-course IMRT in 30 to 33 fractions, one fraction daily over 5 days per week. The brain was contoured primarily by automatic segmentation (errors were corrected by manual contouring) in all cases as only the pure brain parenchyma was considered, excluding the cavernous sinuses, the brainstem, optic chiasm, optical tract, pituitary gland, mammillary bodies, and Meckel’s caves (16, 17). For the purpose of this study, the brain was divided into left half-brain and right half-brain according to the brain midline on coronal image (Figure 1). The temporal lobes contoured (similar to the method 1 in Sun’s study (15) but the basal ganglia and insula were excluded) by the radiotherapists previously were directly adopted.

Toxicity Endpoints

The MRI images were reviewed by two radiologists and a radiation oncologist, and disagreements were resolved by consensus. Diagnostic criteria for TLI were as follows (6): (a) white matter lesions, defined as areas of finger-like lesions of increased signal intensity on T2-weighted images; (b) contrast-enhanced lesions, defined as lesions with or without necrosis on post-contrast T1-weighted images with heterogeneous signal abnormalities on T2-weighted images; (c) cysts, round or oval well defined lesions of very high signal intensity on T2-weighted images with a thin or imperceptible wall as previously reported.

Dosimetric Parameters

The dose-volume histograms (DVH) were exported from the treatment planning system. Dosimetric parameters included...
maximum dose ($D_{\text{max}}$), doses covering certain volume ($D_{V}$) from 0.03 to 20 cc and absolute volumes receiving specific dose ($V_{D}$) from 40 Gy to 80 Gy. Equivalent dose in 2 Gy ($EQD_{2}$) was calculated by linear quadratic model ($EQD_{2}=D_{V}(d_{b}+\alpha\beta)/(2+\alpha\beta)$) (18) with an $\alpha\beta$ ratio of 3 Gy (17).

### Statistical Analysis

SPSS 19.0 was used for statistical analysis. The variations in delineation of temporal lobe, half-brain, and brain were assessed by Coefficients of variation (CV). $D_{V}$s in half-brain and temporal lobe were compared using paired samples $t$-tests. Receiver operating characteristic curve (ROC) was used for screening dosimetric parameters to predict TLI. The prediction ability was assessed by the area under the curve (AUC) and Youden index. Dose and volume response curves were calculated with the nonlinear regression model using the logistic dose/volume response model (19) as $P(X) = 1/(1+\exp(-b_0-b_1X))$, where $X$ is the value of $D_{V}$ or $V_{D}$.

### RESULTS

#### Descriptive Statistics of Volumes, $D_{V}$ and $V_{D}$

Mean volumes of brains, left half-brains, right half-brains, left temporal lobes, and right temporal lobes were 1303.84 ± 126.78 cc, 640.35 ± 63.81 cc, 659.61 ± 64.47 cc, 66.50 ± 18.52 cc, and 70.39 ± 19.95 cc, respectively. CVs of them were 9.72%, 9.96%, 9.77%, 27.85%, and 28.34%, respectively. Paired samples $t$-tests showed that each $D_{V}$ in temporal lobe was significantly smaller than that in half-brain ($P < 0.001$), and the reduction ranged from 3.10% to 45.98% (Table 2). Pearson correlation analysis showed that all the $D_{V}$s in each structure were associated with each other significantly, as well as $V_{D}$s ($P < 0.001$).

#### Variations of ROC in Different Structures

The AUCs of $D_{V}$s and $V_{D}$s showed an "increase -maximum-decline" behavior with a peak as the volume or dose increased (Figure 3). The maximal AUCs of $D_{V}$s in brain, half-brain, and temporal lobe were 0.808 ($D_{0.2cc}$), 0.828 ($D_{1.2cc}$) and 0.806 ($D_{0.6cc}$), respectively. The maximal AUCs of $V_{D}$s in brain, half-brain, and temporal lobe were 0.818 ($D_{0.6cc}$), 0.834 ($D_{2.0cc}$), and 0.814 ($V_{72Gy}$), respectively. The cutoff of $V_{72Gy}$ (0.60 cc) in half-brain showed the largest Youden index (0.568). Further analysis of all the dose/volume points showed that the cutoffs of $V_{70Gy}$ (0.86 cc), $V_{71Gy}$ (0.72 cc), and $V_{73Gy}$ (0.45 cc) in half-brain also had the same or better Youden index (Table 3).

#### Dose/Volume Response Model

Because of significant collinearity of dosimetric parameters, multivariate analysis was not considered. $D_{1.2cc}$ and $V_{72Gy}$ in half-brain were enrolled for dose/volume response model due to better AUC. Independent logistic regression analysis was performed with each dosimetric factor (Table 4). Two dose/volume response curves were generated and demonstrated an increasing effect probability with increasing dose/volume (Figure 3). TD5/5 and TD5/5 of $D_{1.2cc}$ were 58.7 Gy (95% CI: 53.6–63.8) and 80.0 Gy (95% CI: 74.9–85.2), respectively. The probability of TLI was higher than 13% when $V_{72Gy} > 0$ cc (95% CI: 0–2.87), and equal to 50% when $V_{72Gy} = 7.66$ cc (95% CI: 4.79–10.52).

### DISCUSSION

The dosimetric parameters are the major variables that influence the development of radiation-induced TLI. Other suggested risk factors include chemotherapy use, radiation technique, and T stage (5–7, 20). However, T stage is correlated with dose and prescription. When T stage and dose are analyzed together, T stage would be

### TABLE 2 | Comparison of $D_{V}$s in half-brain and temporal lobe.

| Variable | Mean (Gy) | Difference (Gy) | Reduction (%) | $P$ |
|----------|-----------|-----------------|---------------|-----|
|          | half-brain | temporal lobe   |               |     |
| $D_{\text{max}}$ | 78.37 ± 8.86 | 75.94 ± 8.78 | 2.43 ± 4.85 | 3.10 ± 6.19 | <0.001 |
| $D_{0.2cc}$ | 76.30 ± 9.18 | 73.72 ± 9.01 | 2.58 ± 4.88 | 3.38 ± 6.40 | <0.001 |
| $D_{0.5cc}$ | 70.72 ± 10.03 | 67.51 ± 10.19 | 3.20 ± 5.05 | 4.53 ± 7.14 | <0.001 |
| $D_{0.6cc}$ | 70.02 ± 10.16 | 67.63 ± 10.34 | 2.39 ± 4.88 | 4.70 ± 7.23 | <0.001 |
| $D_{2.0cc}$ | 69.37 ± 10.28 | 66.01 ± 10.48 | 3.36 ± 5.05 | 4.84 ± 7.28 | <0.001 |
| $D_{7.0cc}$ | 68.77 ± 10.39 | 65.34 ± 10.61 | 3.43 ± 5.03 | 4.99 ± 7.31 | <0.001 |
| $D_{2.5cc}$ | 68.20 ± 10.49 | 64.70 ± 10.73 | 3.49 ± 5.03 | 5.12 ± 7.38 | <0.001 |
| $D_{1.0cc}$ | 67.66 ± 10.58 | 64.10 ± 10.84 | 3.56 ± 5.03 | 5.30 ± 7.49 | <0.001 |
| $D_{1.4cc}$ | 67.15 ± 10.67 | 63.52 ± 10.93 | 3.63 ± 5.03 | 5.37 ± 7.43 | <0.001 |
| $D_{1.1cc}$ | 66.92 ± 10.71 | 62.97 ± 11.03 | 3.95 ± 5.08 | 5.90 ± 7.59 | <0.001 |
| $D_{1.3cc}$ | 66.21 ± 10.83 | 62.44 ± 11.12 | 3.77 ± 5.07 | 5.69 ± 7.66 | <0.001 |
| $D_{1.2cc}$ | 65.77 ± 10.91 | 61.93 ± 11.19 | 3.84 ± 5.08 | 5.84 ± 7.72 | <0.001 |
| $D_{1.0cc}$ | 65.34 ± 10.97 | 61.43 ± 11.27 | 3.91 ± 5.10 | 5.98 ± 7.81 | <0.001 |
| $D_{0.8cc}$ | 63.40 ± 11.22 | 59.13 ± 11.57 | 4.27 ± 5.18 | 6.73 ± 8.17 | <0.001 |
| $D_{0.5cc}$ | 60.28 ± 11.53 | 55.24 ± 12.06 | 4.04 ± 5.40 | 8.36 ± 9.96 | <0.001 |
| $D_{0.4cc}$ | 57.82 ± 11.69 | 51.94 ± 12.46 | 5.88 ± 5.64 | 10.17 ± 9.76 | <0.001 |
| $D_{0.1cc}$ | 55.78 ± 11.76 | 49.02 ± 12.77 | 6.76 ± 5.78 | 12.12 ± 10.36 | <0.001 |
| $D_{0.0cc}$ | 48.78 ± 11.67 | 37.48 ± 13.84 | 11.3 ± 6.38 | 23.16 ± 13.08 | <0.001 |
| $D_{0.9cc}$ | 40.93 ± 11.19 | 22.11 ± 13.27 | 18.82 ± 7.05 | 45.98 ± 17.22 | <0.001 |
removed by analysis model (21). In order to reduce the influence of chemotherapy use and radiotherapy technique, only the patients who treated with IMRT and concurrent platinum-based chemotherapy were included. In this study, when T stage and the following dosimetric parameters were analyzed together in multivariate analysis, T stage was removed. Therefore, the only independent risk factor was dosimetric parameters in this study.

Because of the long latency period (6, 20, 22, 23), the incidence of radiation-induced TLI may be underestimated if the follow-up is insufficient. Studies have shown an incidence between 0% and 40.3% in NPC patients (6, 20, 24–26). In this study, the higher incidence of TLI may be related to follow-up bias and advanced T-stage (symptomatic patients were more likely to complete follow-up). However, incidence should be estimated based on dosimetric parameters. Predictive models attempt to provide a versatile and objective estimate of a patient’s probability of developing treatment related complications (17). Marks et al. considered that the information provided by QUANTEC is generally not ideal for most of organs, and care must be taken to apply it correctly in the clinic (27). The ideal information might require substantial, more comparable and reliable supporting data. To ensure the accuracy of prediction, target volumes should be highly consistent and repeatable.

Whether the parahippocampal, hippocampus, basal ganglia, and insula were included in temporal lobe was debatable before Sun’s recommendation (15). There is little disagreement regarding

---

**TABLE 3 | The best AUCs and cutoffs in temporal lobe, half-brain, and brain.**

|                | AUC   | 95% CI       | Cutoff                     |
|----------------|-------|--------------|---------------------------|
|                | Lower | Upper        | Value | Sensitivity | Specificity | Youden index |
| Temporal lobe  |       |              |       |            |            |              |
| D0.6cc         | 0.806 | 0.757        | 0.854 | 68.99 Gy    | 0.854       | 0.695        | 0.549        |
| V70Gy          | 0.814 | 0.769        | 0.860 | 0.45 cc     | 0.865       | 0.686        | 0.551        |
| Half-brain     |       |              |       |            |            |              |
| D1.2cc         | 0.828 | 0.783        | 0.872 | 67.49 Gy    | 0.885       | 0.661        | 0.536        |
| V72Gy          | 0.834 | 0.790        | 0.877 | 0.60 cc     | 0.896       | 0.672        | 0.568        |
| V71Gy          | 0.832 | 0.788        | 0.876 | 0.86 cc     | 0.896       | 0.672        | 0.568        |
| V70Gy          | 0.833 | 0.790        | 0.876 | 0.72 cc     | 0.896       | 0.672        | 0.568        |
| V73Gy          | 0.832 | 0.788        | 0.876 | 0.48 cc     | 0.896       | 0.677        | 0.573        |
| V71Gy          | 0.833 | 0.790        | 0.876 | 0.72 cc     | 0.896       | 0.677        | 0.573        |
| Brain          |       |              |       |            |            |              |
| D2cc           | 0.808 | 0.748        | 0.868 | 75.67 Gy    | 0.684       | 0.833        | 0.517        |
| V75Gy          | 0.818 | 0.760        | 0.876 | 2.22 cc     | 0.684       | 0.833        | 0.517        |

**TABLE 4 | Logistic regression analysis results of D1.2cc and V72Gy in half-brain.**

|             | B     | SE    | Wald | Sig     | Exp (B) |
|-------------|-------|-------|------|---------|---------|
| D1.2cc      | 0.138 | 0.016 | 73.840 | <0.001  | 1.148   |
| Constant    | -11.045 | 1.192 | 85.786 | <0.001  | 0.000   |
| V72Gy       | 0.247 | 0.040 | 38.126 | <0.001  | 1.281   |
| Constant    | -1.891 | 0.156 | 147.320 | <0.001  | 0.151   |

**FIGURE 2 | (A) The AUCs of DVs in temporal lobe, half-brain, and brain. (B) The AUCs of VDs in temporal lobe, half-brain, and brain.**
image segmentation of the entire brain, and little movement occurs (2). Brain could be easily contoured by rapidly evolving automatic and robust segmentation technology (28–30). Large volume of temporal lobe is contoured in NPC patients, but only a small hot spot volume about 1 cc is used for prediction in most of the studies (3). The high-dose regions are mainly distributed in bilateral temporal pole in NPC patients, and the intermediate structure, such as brainstem, optic chiasm, optical tract, pituitary gland, and mammillary bodies are excluded from brain delineation (16). Thus the half-brain delineation might replace the temporal lobe delineation in NPC patients, considering that the high-dose regions of two half-brains rarely overlap. In this study, CVs of both brains and half-brains were less than 10%, but the CVs of temporal lobes by manual contouring without rigidly standardized training were close to 30%, indicating that brain and half-brain are more stable structures with less contouring variation.

Compared to DVs in half-brain, DVs in temporal lobe reduced by less than 5% when the volume was less than 0.8 cc, indicating that the hot spot, which is the common predictor, is likely included in both half-brain and temporal lobe although the CV of temporal lobes is large. Therefore, half-brain might be a simple substitute for the temporal lobe. In this study, the maximal AUC in half-brain was better than that in temporal lobe. In addition to the difference in temporal lobe delineation, the possible reason is that parahippocampal and hippocampus were not included in temporal lobe in this study. Therefore, some volumes with high/sub-high dose were excluded, which might affect the prediction ability. To avoid this, parahippocampal and hippocampus should be included in temporal lobe, which is also suggested in Sun’s recommendation (15). While in extreme cases, the highest dose of 1 cc may present outside the temporal lobe, it is not a bad thing that it could predict other brain injury.

Considering that brain structure is defined by international guidelines (16), the predictive ability of brain was also assessed in this study. The results showed that the AUC in brain was lower than that in half-brain. That is probably because the brain including more dispersed hot spots (bilateral dose deposition) could not predict TLI accurately. In this study, the optimal dosimetric parameters and limits of three structures were different, which indicated that target volume should have a high consistency to ensure the reliability of the prediction model.

The AUCs of $D_{VS}/V_{DS}$ in each structure showed an “increase-maximum-decline” behavior with a peak at the volume or dose increased, indicating that the dose of extremely small hot spot volume, such as $D_{max}$ and $D_{0.03cc}$, might not be a reasonable parameter of TLI prediction model. The possible reason is that the small volume of the hot spot is easily influenced by contouring, and easily manipulated by the treatment planner, or by the optimization software. Nevertheless, $D_{max}$ or $D_{0.03cc}$ might be used as a dose monitoring point of tolerated dose. Zhou et al. found that $V_D$ at a dose of $\geq 70$ Gy was found with the highest odds ratio (23). In this study, the $V_D$ points of $V_{72Gy} = 0.45$ cc, $V_{72Gy} = 0.60$ cc, $V_{71Gy} = 0.72$ cc, and $V_{70Gy} = 0.86$ cc had better Youden index, indicating that 70 Gy may be a sensitive and specific cutoff dose. Therefore, $D_{max}/D_{0.03cc} < 70$ Gy might be relatively safe, which is also suggested by international guideline (3).

However, the best cutoff does not mean the best probability prediction parameter. Stable and representative volumes are important to overall predictive capacity. In this study, $D_{1.2cc}$ and $V_{72Gy}$ in half-brain were enrolled for dose/volume response model due to better AUCs. TD5/5 and TD50/5 of $D_{1.2cc}$ were 58.7 and 80.0 Gy, respectively. The probability of TLI was higher than 13% when $V_{72Gy} > 0$ cc, and equal to 50% when $V_{72Gy} = 0.66$ cc. Considering the difference of reference volume, the AUC, TD5/5 and TD50/5 are roughly similar to previous studies (4, 6, 8), indicating that half-brain delineation is feasible for TLI prediction model.

There are several limitations in this study. Firstly, the temporal lobe may have better predictive power after standardized training toward observers, which was not involved in this study. Second, the fraction is not uniform, which may influence the predictive ability. Thirdly, the half-brain delineation method is limited to NPC patients, and new errors may be introduced comparing with only...
delineating temporal lobe. Finally, the application of half-brain delineation needs to be confirmed in more studies, especially in multi-center studies.

CONCLUSION

Half-brain delineation is a convenient and stable method which could reduce contouring variation and could be used in TLI prediction model in NPC patients. D1.2cc and V72Gy of half-brain are feasible for TLI prediction model. TDS/5 and TD50/5 of D1.2cc are 58.7 Gy and 80.0 Gy, respectively. The probability of TLI is higher than 13% when V72Gy>0 cc, and equal to 50% when V72Gy=7.66 cc. The dose below 70 Gy may be relatively safe for half-brain. The cutoff points of V70Gy=0.45 cc, V72Gy=0.60 cc, V71Gy=0.72 cc, and V70Gy=0.86 cc could be considered when the high dose of half-brain is inevitable.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the review board of the Second Affiliated Hospital of Guangxi Medical University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES

1. Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: A review. Front Oncol (2012) 2:73. doi: 10.3389/fonc.2012.00073
2. Lawrence YR, Li XA, el Naqa I, Hahn CA, Merchant TE, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 76(3 Suppl):S20–7. doi: 10.1016/j.ijrobp.2009.02.091
3. Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys (2019) 105(3):567–80. doi: 10.1016/j.ijrobp.2019.06.2540
4. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, et al. Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. BMC Cancer (2013) 13:397. doi: 10.1186/1471-2407-13-397
5. Su SF, Huang Y, Xiao WW, Huang SM, Han F, Xie CM, et al. Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 104(3):312–6. doi: 10.1016/j.ijrobp.2012.06.012
6. Feng M, Huang YC, Fan XG, Xu P, Lang JY, Wang DA. Prognostic variables for temporal lobe injury after intensity modulated radiotherapy of nasopharyngeal carcinoma. Cancer Med (2018) 7(3):557–64. doi: 10.1002/cam4.1291
7. Zeng L, Huang SM, Tian YM, Sun XM, Han F, Lu TX, et al. Normal Tissue Complication Probability Model for Radiation-induced Temporal Lobe Injury after Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma. Radiology (2015) 276(1):243–9. doi: 10.1148/ radiol.14141721

AUTHOR CONTRIBUTIONS

S-YZ and W-QL participated in the study concept and design. JL, F-FL, X-DL, H-JZ, XO, Q-LZ, D-JL, and Z-PZ participated in the acquisition of data. Q-HD and Y-XG participated in the analysis and interpretation of data. Q-HD participated in the statistical analysis. Q-HD and R-SW participated in the drafting of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by Science Foundation of Guangxi Zhuang Autonomous Region Health and Family Planning Commission [award Z20181010& Z20181011] and Science Foundation of Second Affiliated Hospital of Guangxi Medical University [award EFYKY2020008].

ACKNOWLEDGMENTS

We thank all the members of the Department of Radiation Oncology of First/Second Affiliated Hospital of Guangxi Medical University for their support and discussions.

REFERENCES

1. Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: A review. Front Oncol (2012) 2:73. doi: 10.3389/fonc.2012.00073
2. Lawrence YR, Li XA, el Naqa I, Hahn CA, Merchant TE, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 76(3 Suppl):S20–7. doi: 10.1016/j.ijrobp.2009.02.091
3. Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys (2019) 105(3):567–80. doi: 10.1016/j.ijrobp.2019.06.2540
4. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, et al. Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. BMC Cancer (2013) 13:397. doi: 10.1186/1471-2407-13-397
5. Su SF, Huang Y, Xiao WW, Huang SM, Han F, Xie CM, et al. Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 104(3):312–6. doi: 10.1016/j.ijrobp.2012.06.012
6. Feng M, Huang YC, Fan XG, Xu P, Lang JY, Wang DA. Prognostic variables for temporal lobe injury after intensity modulated radiotherapy of nasopharyngeal carcinoma. Cancer Med (2018) 7(3):557–64. doi: 10.1002/cam4.1291
7. Zeng L, Huang SM, Tian YM, Sun XM, Han F, Lu TX, et al. Normal Tissue Complication Probability Model for Radiation-induced Temporal Lobe Injury after Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma. Radiology (2015) 276(1):243–9. doi: 10.1148/ radiol.14141721
8. Kong C, Zhu XZ, Lee TF, Feng PB, Xu JH, Qian PD, et al. LASSO-based NTCP model for radiation-induced temporal lobe injury developing after intensity-modulated radiotherapy of nasopharyngeal carcinoma. Sci Rep (2016) 6:26378. doi: 10.1038/srep26378
9. Eminowicz G, McCormack M. Variability of clinical target volume delineation for definitive radiotherapy in cervix cancer. Radiother Oncol (2015) 117(3):542–7. doi: 10.1016/j.radonc.2015.10.007
10. Hague C, Beasley W, Dixon L, Gaito S, Garcez K, Green A, et al. Use of a novel atlas for muscles of mastication to reduce inter observer variability in head and neck radiotherapy contouring. Radiother Oncol (2019) 135:56–61. doi: 10.1016/j.radonc.2018.10.030
11. Alasti H, Cho YB, Catton C, Berlin A, Chung P, Bayley A, et al. Evaluation of high dose volumetric CT to reduce inter-observer delineation variability and PTV margins for prostate cancer radiotherapy. Radiother Oncol (2017) 125(1):118–23. doi: 10.1016/j.radonc.2017.08.012
12. Baxi S, Park E, Chong V, Chung HT. Temporal changes in IMRT contouring of organs at risk for nasopharyngeal carcinoma - the learning curve blues and a tool that could help. Technol Cancer Res Treat (2009) 8(2):131–40. doi: 10.1177/153303460900800206
13. Ho F, Tey J, Chia D, Soon YY, Tan CW, Bahiah S, et al. Implementation of temporal lobe contouring protocol in head and neck cancer radiotherapy planning: A quality improvement project. Med (Baltimore) (2018) 97(38):e12381. doi: 10.1097/MD.0000000000012381
14. Lu LX, Sheng Y, Zhang GS, Li YZ, Ouyang PY, Ge YR, et al. Temporal lobe injury patterns following intensity modulated radiotherapy in a large cohort of nasopharyngeal carcinoma patients. Oral Oncol (2018) 85:8–14. doi: 10.1016/j.oraloncology.2018.07.020
15. Sun Y, Yu XL, Luo W, Lee AW, Wee JT, Lee N, et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma.
patients receiving intensity-modulated radiotherapy. *Radiother Oncol* (2014) 110(3):390–7. doi: 10.1016/j.radonc.2013.10.035

16. Broecker CL, Steemhckers RJ, Bourhis J, Budach W, Grau C, Gregoire V, et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. *Radiother Oncol* (2015) 117 (1):83–90. doi: 10.1016/j.radonc.2015.07.041

17. Niyazi M, Niemierko A, Paganetti H, Sohn M, Schapira E, Goldberg S, et al. Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. *Radiother Oncol* (2020) 142:154–61. doi: 10.1016/j.radonc.2019.09.008

18. Dujim M, van der Voort van Zyp NC, van de Vaart P, Oomen-de Hoop E, Mast ME, Hoogeman MS, et al. Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model. *Int J Radiat Oncol Biol Phys* (2020) 106(1):73–81. doi: 10.1016/j.ijrobp.2019.08.059

19. Troeller A, Yan D, Marina O, Schulze D, Alber M, Parodi K, et al. Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis. *Int J Radiat Oncol Biol Phys* (2015) 91(2):435–43. doi: 10.1016/j.ijrobp.2014.09.046

20. Zhou GQ, Yu XL, Chen M, Guo R, Lei Y, Sun Y, et al. Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy. *PLoS One* (2013) 8(7):e67488. doi: 10.1371/journal.pone.0067488

21. Wang J, Miao Y, Ou X, Wang X, He X, Shen C, et al. Development and validation of a model for temporal lobe necrosis for nasopharyngeal carcinoma patients with intensity modulated radiotherapy. *Radiother Oncol* (2019) 141(1):42. doi: 10.1016/s13014-019-1250-2

22. Su SF, Huang SM, Han F, Huang Y, Chen CY, Xiao WW, et al. Analysis of dosimetric factors associated with temporal lobe necrosis (TLN) in patients with nasopharyngeal carcinoma (NPC) after intensity modulated radiotherapy. *Radiother Oncol* (2013) 8:17. doi: 10.1186/1748-717X-8-17

23. Zhou X, Ou XM, Xu TT, Wang XS, Shen CY, Ding JH, et al. Effect of Dosimetric Factors on Occurrence and Volume of Temporal Lobe Necrosis Following Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma: A Case-Control Study. *Int J Radiat Oncol Biol Phys* (2014) 90(2):261–9. doi: 10.1016/j.ijrobp.2014.05.036

24. Lee AWM, Kwong DLW, Leung SF, Tung SY, Sze WM, Sham JST, et al. Factors affecting risk of symptomatic temporal lobe necrosis: Significance of fractional dose and treatment time. *Int J Radiat Oncol Biol Phys* (2002) 53(1):75–85. doi: 10.1016/S0360-3016(02)02711-6

25. Lee AW, Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, et al. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* (1998) 40 (1):35–42. doi: 10.1016/s0360-3016(97)00580-4

26. Jen YM, Hsu WL, Chen CY, Hwang JM, Chang LP, Lin YS, et al. Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques. *Int J Radiat Oncol Biol Phys* (2001) 51 (2):344–8. doi: 10.1016/s0360-3016(01)01631-5

27. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of Normal Tissue Complication Probability Models in the Clinic. *Int J Radiat Oncol Biol Phys* (2010) 76(3):S10–S9. doi: 10.1016/j.ijrobp.2009.07.1754

28. Men K, Zhang T, Chen XY, Chen B, Tang Y, Wang SL, et al. Fully automatic and robust segmentation of the clinical target volume for radiotherapy of breast cancer using big data and deep learning. *Phys Med* (2018) 50:13–9. doi: 10.1016/j.ejmp.2018.05.006

29. Men K, Dai JR, Li YX. Automatic segmentation of the clinical target volume and organs at risk in the planning CT for rectal cancer using deep dilated convolutional neural networks. *Med Phys* (2017) 44(12):6377–89. doi: 10.1002/mp.12662

30. Yang JZ, Beadle BM, Garden AS, Schwartz DL, Aristophanous M. A multimodality segmentation framework for automatic target delineation in head and neck radiotherapy. *Med Phys* (2015) 42(9):5310–20. doi: 10.1118/1.4928485

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.